Helius Medical Technologies, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The filing identifies the registrant as Helius Medical Technologies, Inc.; this does not match the request metadata naming Solana Co. Financial amounts below are in U.S. dollars; tables report amounts in thousands unless noted.
Business context and key financial metrics
Helius is a neurotechnology company commercializing its PoNS device and therapy, primarily for gait and balance deficits. U.S. sales began in 2022; the product is also sold in Canada. The company reports one operating segment.
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Total revenue | $135 | $111 | Up $24, or about 22%; product sales were $124 |
| Gross profit (loss) | $12 | ($11) | Gross margin about 9%, versus about negative 10% |
| Operating expenses | $3,428 | $3,799 | Down $371 |
| Operating loss | ($3,416) | ($3,810) | Improved by $394 |
| Net loss | ($2,516) | ($2,494) | Loss widened by $22 |
| Operating cash used | ($3,001) | ($3,190) | Cash use decreased by $189 |
| Cash and cash equivalents | $3,638 at March 31 | $5,182 at December 31, 2023 | Quarterly decrease of $1,544 |
| Working capital | $3,948 | $5,559 at December 31, 2023 | Decreased by $1,611 |
| Total liabilities | $3,771 | $5,342 at December 31, 2023 | Includes $2,080 derivative liability and lease/deferred revenue obligations |
No conventional interest-bearing debt balance is identified in the supplied filing text. The derivative liability relates to warrants and is remeasured at fair value. Basic and diluted loss per share were both reported as $3.08; weighted-average shares were 817,327, versus 564,134 in Q1 2023. The filing’s financial statements reflect a prior 1-for-50 reverse split.
Material changes and management commentary
- Product sales increased to $124 from $106, with U.S. sales of $79 and Canadian sales of $45. Management described sales as comparable year over year.
- SG&A declined $241, mainly from lower professional fees and payroll-related costs, partly offset by higher contract-manufacturer expense. R&D fell $98 as activity shifted from product development and clinical trials toward U.S. commercialization.
- Net loss was affected by a smaller noncash gain on the warrant derivative liability ($1,142 versus $1,221), a $288 foreign-exchange loss versus $5, and lower net interest income. The derivative fair-value gain was primarily attributed to a lower share price.
- Financing activities provided $1,463, including $1,374 from common stock issuance and $162 from warrant exercises, partly offset by offering-related costs. The company sold shares through its ATM program.
- Customer concentration increased: two customers represented 94% of Q1 2024 product sales and 94% of accounts receivable at March 31, 2024.
Outlook, risks and contingencies
- Going concern: Management states that recurring losses and cash outflows create substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements are filed. It expects continued losses and says additional capital will be needed after available resources are used.
- Runway and funding: Management expected cash on hand together with the approximately $5.6 million net proceeds from a May 9, 2024 offering to fund operations into 2025. It expects to seek additional equity or debt funding thereafter and says planned stroke clinical trials will require additional funding. No assurance is given that financing will be available on acceptable terms.
- Subsequent offering and dilution: The May 9 offering included common shares, pre-funded warrants and Series A and Series B warrants, with approximately $5.6 million net proceeds. The transaction also triggered repricing of the outstanding 2022 warrants. Verify the resulting share count, warrant terms and dilution.
- Reimbursement and commercialization: PoNS was not covered by CMS or reimbursed by U.S. third-party payers as of the filing. CMS assigned HCPCS codes effective April 1, 2024 and published preliminary payment rates for discussion; management was seeking final payment determinations targeted to take effect October 1, 2024. Management anticipates broad payer coverage may take at least 24 months after the codes become effective and expects self-pay to be the primary sales channel before coverage.
- Clinical and manufacturing plans: Stroke studies were underway, with enrollment expected to finish by year-end 2024 and an FDA submission targeted for mid-to-late 2025. The transition to Minnetronix as contract manufacturer was expected to be completed in Q3 2024; delays or disruption could harm the business.
- Nasdaq listing: Nasdaq notified the company that it did not meet the $2.5 million stockholders’ equity requirement, based on equity reported in its 2023 10-K. The company intended to submit a compliance plan; the notice had no immediate effect on trading. The subsequent offering occurred after quarter-end.
- The company cites macroeconomic volatility, inflation, supply-chain and labor constraints, global conflicts, capital-market access, clinical and regulatory outcomes, reimbursement, manufacturing, and the ability to build commercial infrastructure as risks. It reported no material legal proceedings and no material change to previously disclosed risk factors other than the manufacturing-transition risk.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Helius Medical Technologies, Inc., not Solana Co.
- Review the May 2024 offering, warrant repricing and post-offering fully diluted share count.
- Track cash burn, liquidity and whether management’s stated runway into 2025 remains achievable; the filing expressly identifies substantial going-concern doubt.
- Verify final CMS reimbursement rates, effective dates, and progress toward commercial payer coverage and sales growth.
- Monitor completion of the manufacturer transition, stroke-study enrollment and FDA submission timeline.
- Assess dependence on two customers, the warrant derivative’s noncash fair-value volatility, and Nasdaq compliance status.